Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.
about
Variation in sepsis care: a wake-up callOutcomes research in the development and evaluation of practice guidelinesDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsSurveillance epidemiology and end results analysis demonstrates improvement in overall survival for cervical cancer patients treated in the era of concurrent chemoradiotherapyUsing marketing principles for healthcare development.Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.The effects of information framing on the practices of physiciansGetting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project.Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995.Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model.Applying the results of clinical trials to patients to general practice: perceived problems, strengths, assumptions, and challenges for the future.Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference?Canadian atrial fibrillation anticoagulation study: were the patients subsequently treated with warfarin? Canadian Atrial Fibrillation Anticoagulation Study Group.Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician surveyUndertreatment of hyperlipidemia in the secondary prevention of coronary artery diseaseAtherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease.Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure. Effect of physician specialty and patient characteristicsbeta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.From evidence to clinical practice in blood and marrow transplantationDo surgical trials meet the scientific standards for clinical trials?Lowering physician hospital resource consumption using low-cost low-technology computingTrends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.A survey of management practices for isolated systolic hypertension.The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario.Barriers and Strategies for Recruitment of Racial and Ethnic Minorities: Perspectives from Neurological Clinical Research Coordinators.Meaningful interpretation of risk reduction from clinical drug trials.Pacemaker mode selection and survival: a plea to apply the principles of evidence based medicine to cardiac pacing practice.Aspirin and suspected myocardial infarction: a life-saving treatment we too often forget.Enhancing the quality and visibility of African medical and health journals.VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm.Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery.Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register.Has hospital mortality from acute myocardial infarction been markedly reduced since the introduction of thrombolytics and aspirin? European Secondary Prevention Study Group.Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators.Adjusting Estimates of the Expected Value of Information for Implementation: Theoretical Framework and Practical Application.International trials and national practice: a questionnaire survey of current physician practice in the treatment of acute myocardial infarction.Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive MycosesHow Many “Me-Too” Drugs are Enough? The Case of Physician Preferences for Specific Statins
P2860
Q24795179-85BEE552-2F66-40AB-BD2C-797D2CE937FCQ24806205-0ABA70F7-0960-4D04-ABA0-F0B7F06A45CEQ28200895-837757FA-8580-4BC9-82BB-5982C268B3DFQ30638608-2C683BAD-83CF-4F4C-81EA-7E81BAB24FCFQ33691771-311A7526-16C1-45C9-B8FC-E722998F8EC9Q33711285-8CE23B6B-1989-4659-8BAE-DDEBB1F8DB00Q33735342-8CF074A1-B0D2-4D6C-B2B2-CE1E56C577D2Q33778872-474455B3-4FF4-4662-8E07-7BF4CFA992B3Q33964895-4033C18D-B995-4D62-86D7-65984989C281Q34038103-432C1DC7-DE8B-4886-8686-0880CF8D0180Q34372885-EC137157-A4CA-4B74-BF95-8C9C20DE60FFQ34469512-EC755278-3FF4-4E97-8CC6-FCBA4C22A8EFQ34708340-13832344-A6F2-4B5A-B809-31C90B6F4062Q34712455-4DEB043F-070E-455E-BD5F-FCE9FEF5AAC6Q34743538-3B02F4CE-1069-4E98-8FA4-EE4EA75BE1F4Q34751162-E39A2402-F847-40F7-9EFC-C7BBB3829B3DQ34752879-64AB7863-B962-4EF7-B058-4D7C4A24AD4EQ34753616-E6282D15-3041-47FE-843A-87D81A83CFDEQ35370417-BC130AB5-254E-4800-9248-A86A1C835204Q36176911-DE9BD746-B9D0-4A98-9970-EE1384BAF7F0Q36339313-55A23A45-BCEC-4AFA-95EF-32DC588F975FQ36963639-3107D1E7-3969-43A5-A55A-7375CD185B91Q37656444-B3A12953-5833-4D4C-98A1-AB0C78E6A1AFQ39454311-64561752-55C7-4C95-84CA-5FA710170625Q39731644-9D7381A9-791A-4372-AE1E-7DFE5BC8292DQ40345371-D43C6CE1-441C-488C-B3C6-9CE1FD2CDE49Q40785855-4EE42751-C959-4E44-8A5E-8CD94DEAE3B5Q41344819-BCFBF9B0-39F9-4D27-AFBD-B408B0B57850Q42060361-1206A537-DA66-498A-817C-1E37F2F0D8C4Q43230811-E2A85FD4-0B04-4336-8F94-4D9F2B1C85A6Q44551638-1DB7F5A6-9124-4D3F-A701-676277BAD383Q46471450-A0831746-F310-4EE7-94BF-10E3E36B78E1Q47686239-7D2192CF-EE78-4903-8FD6-1D3F75F7ECE6Q47804414-2EE37581-1833-460A-9057-512BCABE1D62Q47972717-33BAD7D6-033D-4A6A-8749-C06EDE1DB8A4Q50532954-F20B8DFB-B45F-443E-B623-6BB14F1DBA9EQ53284749-7929EB91-A838-44E2-9774-ECC24063E123Q53366733-26F32767-FE4B-4D30-ACD1-8F6611874287Q56837353-E7E550C3-94D6-4E86-BDEF-8881046835A3Q57266853-3EABB765-B8E7-4558-A1E8-5BC042B125AA
P2860
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Do the results of randomized c ...... ctice? The SAVE Investigators.
@en
Do the results of randomized c ...... ctice? The SAVE Investigators.
@nl
type
label
Do the results of randomized c ...... ctice? The SAVE Investigators.
@en
Do the results of randomized c ...... ctice? The SAVE Investigators.
@nl
prefLabel
Do the results of randomized c ...... ctice? The SAVE Investigators.
@en
Do the results of randomized c ...... ctice? The SAVE Investigators.
@nl
P2093
P1476
Do the results of randomized c ...... ctice? The SAVE Investigators.
@en
P2093
P304
P356
10.1056/NEJM199207233270405
P407
P577
1992-07-01T00:00:00Z